These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Assessment of humoral and cellular immune responses to SARS CoV-2 vaccination (BNT162b2) in immunocompromised renal allograft recipients. Zhang R; Shin BH; Gadsden TM; Petrosyan A; Vo A; Ammerman N; Sethi S; Huang E; Peng A; Najjar R; Atienza J; Kim I; Jordan SC Transpl Infect Dis; 2022 Apr; 24(2):e13813. PubMed ID: 35202497 [TBL] [Abstract][Full Text] [Related]
13. Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies. Kohmer N; Rabenau HF; Ciesek S; Krämer BK; Göttmann U; Keller C; Rose D; Blume C; Thomas M; Lammert A; Lammert A Nephrol Dial Transplant; 2022 May; 37(6):1132-1139. PubMed ID: 35099023 [TBL] [Abstract][Full Text] [Related]
14. Impaired Immune Response to SARS-CoV-2 Vaccination in Dialysis Patients and in Kidney Transplant Recipients. Kolb T; Fischer S; Müller L; Lübke N; Hillebrandt J; Andrée M; Schmitz M; Schmidt C; Küçükköylü S; Koster L; Kittel M; Weiland L; Dreyling KW; Hetzel G; Adams O; Schaal H; Ivens K; Rump LC; Timm J; Stegbauer J Kidney360; 2021 Sep; 2(9):1491-1498. PubMed ID: 35373105 [TBL] [Abstract][Full Text] [Related]
15. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections. Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G Front Immunol; 2022; 13():863554. PubMed ID: 35711445 [TBL] [Abstract][Full Text] [Related]
16. Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc study. Stumpf J; Schwöbel J; Lindner T; Anders L; Siepmann T; Karger C; Hüther J; Martin H; Müller P; Faulhaber-Walter R; Langer T; Schirutschke H; Stehr T; Meistring F; Pietzonka A; Anding-Rost K; Escher K; Pistrosch F; Schewe J; Seidel H; Barnett K; Pluntke T; Cerny S; Paliege A; Bast I; Steglich A; Gembardt F; Kessel F; Kröger H; Arndt P; Sradnick J; Frank K; Klimova A; Mauer R; Grählert X; Tonn T; Hugo C Lancet Reg Health Eur; 2022 Jun; 17():100371. PubMed ID: 35434688 [TBL] [Abstract][Full Text] [Related]
17. Prediction of humoral and cellular immune response to COVID-19 mRNA vaccination by TTV load in kidney transplant recipients and hemodialysis patients. Graninger M; Stumpf J; Bond G; Görzer I; Springer DN; Kessel F; Kröger H; Frank K; Tonn T; Hugo C; Puchhammer-Stöckl E J Clin Virol; 2023 May; 162():105428. PubMed ID: 36989730 [TBL] [Abstract][Full Text] [Related]
18. MMF/MPA Is the Main Mediator of a Delayed Humoral Response With Reduced Antibody Decline in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination. Stumpf J; Siepmann T; Schwöbel J; Glombig G; Paliege A; Steglich A; Gembardt F; Kessel F; Kröger H; Arndt P; Sradnick J; Frank K; Klimova A; Mauer R; Tonn T; Hugo C Front Med (Lausanne); 2022; 9():928542. PubMed ID: 35872777 [TBL] [Abstract][Full Text] [Related]
19. Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients. Davidovic T; Schimpf J; Abbassi-Nik A; Stockinger R; Sprenger-Mähr H; Lhotta K; Zitt E Front Immunol; 2022; 13():907615. PubMed ID: 35812459 [TBL] [Abstract][Full Text] [Related]
20. Humoral immune response after different SARS-CoV-2 vaccination regimens. Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]